QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.104315v1 318/3/1178    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gass, J. Articles by Khosla, C. Search for Related Content PubMed PubMed Citation Articles by Gass, J. Articles by Khosla, C.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Effect of Barley Endoprotease EP-B2 on Gluten Digestion in the Intact Rat

Celiac Sprue Research Foundation, Palo Alto, California (J.G., H.V., G.M.G., C.K.); and Departments of Chemical Engineering (J.G., H.V., C.K.), Biochemistry (M.T.B.), Medicine (G.M.G.), and Chemistry (C.K.), Stanford University, Stanford, California

Celiac Sprue is a multifactorial disease characterized by an intestinal inflammatory response to ingested gluten. Proteolytically resistant gluten peptides from wheat, rye, and barley persist in the intestinal lumen and elicit an immune response in genetically susceptible individuals. Here, we demonstrate the in vivo ability of a gluten-digesting protease ("glutenase") to accelerate the breakdown of a gluten-rich solid meal. The proenzyme form of endoprotease B, isoform 2 from Hordeum vulgare (EP-B2), was orally administered to adult rats with a solid meal containing1gof gluten. Gluten digestion in the stomach and small intestine was monitored as a function of enzyme dose and time by high-performance liquid chromatography and mass spectrometry. In the absence of supplementary EP-B2, gluten was solubilized and proteolyzed to a limited extent in the stomach and was hydrolyzed and assimilated mostly in the small intestine. In contrast, EP-B2 was remarkably effective at digesting gluten in the rat stomach in a dose- and time-dependent fashion. At a 1:25 EP-B2/gluten dose, the gastric concentration of the highly immunogenic 33-mer gliadin peptide was reduced by more than 50-fold within 90 min with no overt signs of toxicity. Evaluation of EP-B2 as an adjunct to diet control is therefore warranted in celiac patients.

Address correspondence to: Chaitan Khosla, 380 Roth Way, Keck Chemistry Building, Stanford University, Stanford, CA 94305. E-mail: khosla{at}stanford.edu

This article has been cited by other articles:

				N. Cerf-Bensussan, T. Matysiak-Budnik, C. Cellier, and M. Heyman Oral proteases: a new approach to managing coeliac disease Gut, February 1, 2007; 56(2): 157 - 160. [Abstract] [Full Text] [PDF]